ACE2 coding variants in different populations and their potential impact on SARS-CoV-2 binding affinity
- PMID: 32844124
- PMCID: PMC7439997
- DOI: 10.1016/j.bbrep.2020.100798
ACE2 coding variants in different populations and their potential impact on SARS-CoV-2 binding affinity
Abstract
The susceptibility of different populations to SARS-CoV-2 infection is not yet understood. Here, we combined ACE2 coding variants' analysis in different populations and computational chemistry calculations to probe the effects on SARS-CoV-2/ACE2 interaction. ACE2-K26R; which is most frequent in Ashkenazi Jewish population decreased the SARS-CoV-2/ACE2 electrostatic attraction. On the contrary, ACE2-I468V, R219C, K341R, D206G, G211R increased the electrostatic attraction; ordered by binding strength from weakest to strongest. The aforementioned variants are most frequent in East Asian, South Asian, African and African American, European, European and South Asian populations, respectively.
Keywords: ACE2 variants; Populations; SARS-CoV-2 binding; Single nucleotide variants.
© 2020 The Authors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.Chem Biol Interact. 2022 Dec 1;368:110244. doi: 10.1016/j.cbi.2022.110244. Epub 2022 Nov 3. Chem Biol Interact. 2022. PMID: 36336003 Free PMC article.
-
Human ACE2 Polymorphisms from Different Human Populations Modulate SARS-CoV-2 Infection.Viruses. 2022 Jun 30;14(7):1451. doi: 10.3390/v14071451. Viruses. 2022. PMID: 35891433 Free PMC article.
-
ACE2 and FURIN variants are potential predictors of SARS-CoV-2 outcome: A time to implement precision medicine against COVID-19.Heliyon. 2021 Feb;7(2):e06133. doi: 10.1016/j.heliyon.2021.e06133. Epub 2021 Jan 28. Heliyon. 2021. PMID: 33532652 Free PMC article.
-
The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy.Front Cell Infect Microbiol. 2021 Oct 22;11:753721. doi: 10.3389/fcimb.2021.753721. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34746028 Free PMC article. Review.
-
How Do Point Mutations Enhancing the Basic Character of the RBDs of SARS-CoV-2 Variants Affect Their Transmissibility and Infectivity Capacities?Viruses. 2022 Apr 10;14(4):783. doi: 10.3390/v14040783. Viruses. 2022. PMID: 35458513 Free PMC article. Review.
Cited by
-
Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages.Comput Biol Med. 2022 Sep;148:105903. doi: 10.1016/j.compbiomed.2022.105903. Epub 2022 Jul 20. Comput Biol Med. 2022. PMID: 35932731 Free PMC article.
-
Variants in ACE2; potential influences on virus infection and COVID-19 severity.Infect Genet Evol. 2021 Jun;90:104773. doi: 10.1016/j.meegid.2021.104773. Epub 2021 Feb 17. Infect Genet Evol. 2021. PMID: 33607284 Free PMC article. Review.
-
The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant.Med Drug Discov. 2021 Jun;10:100086. doi: 10.1016/j.medidd.2021.100086. Epub 2021 Mar 2. Med Drug Discov. 2021. PMID: 33681755 Free PMC article.
-
Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.J Genet. 2021;100(1):12. doi: 10.1007/s12041-021-01262-w. J Genet. 2021. PMID: 33707363 Free PMC article. Review.
-
Genetic and epigenetic factors associated with increased severity of Covid-19.Cell Biol Int. 2021 Jun;45(6):1158-1174. doi: 10.1002/cbin.11572. Epub 2021 Mar 1. Cell Biol Int. 2021. PMID: 33590936 Free PMC article. Review.
References
-
- Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. doi: 10.1016/j.cell.2020.02.052. e8. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous